MBXCX | MBXIX | MBXCX / MBXIX | |
Total Expense Ratio | 3.03 | 2.03 | 149% |
Annual Report Gross Expense Ratio | 3.03 | 2.03 | 149% |
Fund Existence | 9 years | 9 years | - |
Gain YTD | -2.586 | -2.190 | 118% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 2500 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.03B | 8.03B | 100% |
Annual Yield % from dividends | 0.97 | 1.92 | 51% |
Returns for 1 year | -1.98 | -0.99 | 200% |
Returns for 3 years | 4.54 | 7.87 | 58% |
Returns for 5 years | 44.99 | 52.64 | 85% |
Returns for 10 years | N/A | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SHPAX | 18.99 | N/A | N/A |
Saratoga Health & Biotechnology A | |||
GSMGX | 13.59 | N/A | N/A |
Goldman Sachs Small/Mid Cap Growth C | |||
JLCYX | 69.59 | N/A | N/A |
JHancock Fundamental Large Cap Core R2 | |||
BPIRX | 14.18 | N/A | N/A |
Boston Partners Long/Short Rsrch Instl | |||
REQCX | 41.54 | -0.09 | -0.22% |
Russell Sustnbl Aware Eq C |